Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells

British Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 873-879

  Ojugo, A S E ^a,b   McSheehy, P M J ^a,b   Stubbs, M ^a   Alder, G ^a   Bashford, C L ^a   Maxwell, R J ^c   Leach, M O ^b   Judson, I R ^b   Griffiths, J R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

5 fluorouracil; Ascites tumour cells; Extracellular pH; Intracellular pH; pH gradient

Indexed keywords

DIMETHADIONE; FLUOROURACIL; SODIUM;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL PH; CELL STRAIN HT29; CONTROLLED STUDY; CULTURE MEDIUM; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; EHRLICH ASCITES TUMOR CELL; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTON MOTIVE FORCE;

EID: 0031912871     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.144     Document Type: Article

References (31)

1. Aschele C, Sobrero A, Faderan MA and Bertino JR (1992) Novel mechanism(s) of resistance in 5-fluorouracil in human colon cancer HCT-8 sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52: 1855-1864
2. Au LS, Walker JS and Rustum Y (1983) Pharmacokinetic studies of:5-fluorouracil and 5′-deoxy-5-fluorouridine in rats. J Pharmacol Exp Ther 227: 174-180
3. Bashford CL (1994) Measurement of ion fluxes and pH gradients across cell membranes. In Methods in Molecular Biology, 27: Biomembrane Protocols: II Architecture and Function, Graham JM and Higgins JA (eds), pp. 307-323. Humana Press: Totowa, NJ
4. Bashford CL and Pasternak CA (1984). Plasma membrane potential of Lettre cells does not depend on cation gradients but on pumps. J Membrane Biol 79: 275-284
5. Bashford CL, Alder G, Micklem, KJ and Pasternak CA (1983) A novel method for measuring intracellular pH and potassium concentration. Bioscience Reports 3: 631-642
6. Bergmeyer HU (1974) Methods of enzymatic analysis. Weinheim, Deutschland: Verlag Chemie.
7. Cohen JL, Irwin LE, Marshall GJ and Bateman JR (1982) Clinical pharmacology of 5-fluorouracil. Cancer Chem Rep 58: 723-728
8. Dawson RMC, Elliot DC, Elliot WH and Jones KM (1969). Data for Biochemical Research, 2nd edn, pp. 484. Clarendon: Oxford. UK
9. 19F nuclear magnetic resonance spectroscopy. Cancer Res 51: 5806-5812
10. Findlay M and Leach MO (1994). In vivo monitoring of fluoropyrimidine metabolites: Magnetic Resonance Spectroscopy in evaluation of 5-fluorouracil. Anticancer Drugs 5: 260-280
11. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann Oncol 4: 597-602
12. Findlay MP, Raynaud F, Cunningham D, Iveson A, Collins DJ and Leach MO (1996) Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted infusion with or without interferon-α. Annals Oncol 7: 47-53
13. Gerweck LE, Rhee JG, Koutcher JA, Song CW and Urano M (1991) Regulation of pH in murine tumour and muscle. Radiation Res 12: 206-209
14. Griffiths JR (1991) Are cancer cells acidic? Br J Cancer 64: 425-427
15. 19F nuclear magnetic resonance spectroscopy. Cancer Res 51: 5770-5773
16. Harrison R and Lunt GC (1980) Biological Membranes, Structure and Function, 2nd edn, pp. 184. Blackie: London
17. Heidelberger C, Chaudhuari NK, Danenberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and Scheiner J (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179: 663-666
18. Heidelberger C, Danenberg PV and Moran RG (1983) Fluorinated pyrimidines and their nucleosides. Adv Enzymol Rel Areas Mol Biol 54: 58-119
19. Hill SR and Bibby MC (1994) 5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice. Cancer Chemother Pharmacol 34: 57-62
20. 19F NMR spectroscopy. NMR Biomed 4: 274-278
21. 31P magnetic resonance spectroscopy. Eur J Cancer 33: (in press).
22. Maheshwari RK, Sidhu GS, Bhartiya D and Friedman RM (1991) Primary amines enhance the antiviral activity ot Interferon against a membrane virus: role of intracellular pH. J Gen Virol 72: 2143-2152
23. Naguib FNM, el Kouni MH and Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412
24. Peters GJ, Lankelma J, Kok RM, Noordhuis P, van Groeningen CJ, van der Wilt CL, Meyer S and Pinedo HM (1993) Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumours as compares with plasma. Cancer Chemother Pharmacol 31: 269-276
25. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 8: 1868-1873
26. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blaynay D and Brechner RR (1994) Association of intratumoral pharmacokinetics of 5-fluorouracil with clinical response. Lancet 343: 1184-1187
27. 31P MRS as a method of measuring pH in rat tumours. NMR Biomed 5: 351-359
28. Vaupel P, Kallinowski F and Okunieff P (1989). Blood flow, oxygen and nutrient supply, the metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465
29. Wohlhueter RM, McIvor RS and Plagemann PGW (1980) Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 104: 309-319
30. 19F NMR spectroscopic pharmacokinetics in tumour-bearing humans and rabbits. Proc Natl Acad Sci USA 87: 492-496
31. Yamamoto S-I and Kawasaki T (1981) Active transport of 5-fluorouracil and its energy coupling in Ehrlich ascites tumour cells. J Biochem 90: 635-642